Conventional “early detection” is based on medical imagery, including, but not limited to Pep scans, mri, xrays, mammograms, biomarkers like psa and hpv pap smear tests and a few other diagnostic tools, most of which are not early and can be invasive, expensive and inaccurate. Worse, none of the mainstream early detesting and detection interventions look for circulatory cancer stem cells. Yet, these are the cells that are at the root of malignancies. (Source)
Regarding breast cancer, by the time a tumor is seen on a mammogram, up to 8 years can have accumulated. Futhermore, these x-ray based machines have a 4 percent cancer risks with at least 20 percent false readings (false positive and false negative). (1)
Below are a few earlier detection tools the ACR Institute prefers, most of which can also be used as monitoring techniques to evaluate the response potential of a given treatment.
1 CIRCULATORY TUMOR AND STEM CELL TESTS
Evaluating the molecular biology of the tumor cell population and its CTC. (CTC – Circulating tumor cells) is an important part of cancer testing that is missed by most conventional oncologists. By far, the most important test is this one because tumor circulatory stem cells can shed from a 2mm tumor and these are the cells that are the engins of metastases, from which most cancer patients die. For an understanding of circulatory Tumor and cancer stem cells, see this Source. In the United States, the best place to order this test can be ordered at the Cell Search Link.
2. CHEMO-SENSITIVITY & GENOMIC TESTS (molecular cancer diagnostics)
Chemo-sensitivity and genomic testing are useful when the patient uses chemotherapeutic agents and even some supplements. These tools can help to individualized protocols thereby finding the most effective and safest pharmaceutical and neutraceutical interventions. (2) These tests can be ordered via the links below:
1. The Greek RGCC test has a 2 week turnaround time. It can cost $2700 – $3000 depending on the exchange rate and is not usually reimbursable by insurance.
3. Dr Nagourney in California proposes a smilar tests, but for more expensive, at around 4000 dollars. Furthermore, Dr Nagourney only tests the primary tumor and usually required a large biopsy.
This test has high accurate and tells the client where most of the cancers are located. This test is based on the discovery of a cancer-specific universal cancer marker called ENOX2, which is a growth-related protein that appears on the surface of cancer cell only and is then released into the blood stream. If the ENOX2 protein is found, the ONCOblot can then identify 27 different types of cancer as well as the organ of origin. These results give patients time and ability to have very targeted treatments. The ONCOblot test is so sensitive that it detects as few as 2 million cancer cells which is equivalent to 0.8mm or .03 inch, which is size of the period mark at the end of this sentence. It can be ordered via the link below. This test can be directly order via its producer in Germany.
4. CANCER PROFILE TEST
The Cancer Profile test is based on the premise that detectable biochemical changes occur in the human body during its transformation into a cancerous state. It is composed of 8 tests: HCG (human chorionic gonadotropin), tested under 3 different angles, serum chemiluminescence assay and immunoradiometric assay, and urine quantitative chemiluminescence assay; the PHI (phosphohexose isomerase enzyme); CEA (carcinoembryonic antigen); GGTP (gamma-glutamyltranspeptidase);TSH (thyroid-stimulating hormone); and DHEA-S (dehydroepiandrosterone sulfate). Dr. Schandl, the developer of this test, has observed marker elevations in patients as many as 10 to 12 years prior to diagnosis. Knowing that the developmental process of cancer takes 10 to12 years, one may be able to detect the very beginning of cancer, allowing plenty of time to make lifestyle adjustment corrections and take in key supplements and other holistic techniques in order to avoid carcinogenesis.
This test can be used not only for early detection, but also for clinical laboratory follow-up and monitoring disease reduction or progression. Consider the fact, testing for HCG alone can result in approximately 30% false negative results. The entire Cancer Profile may miss only 10-15% cancer positive patients. (2) This test can be ordered directly from the producer, located in Florida, US. (3)
5. THE NAGALESE BLOOD TEST
The Nagalase test is a simple blood test that measures the presence of the enzyme Nagalase. Nagalase is produced by cancer cells (and some viruses) and not by healthy cells. Any amount of Nagalase in the blood means that there are cancer cells that are multiplying and dividing. It has been shown that nagalase basically undermines the Immune System so that the macrophages that gobble up and dismantle cancer cells can no longer do their job. (4)
The strong point of this Nagalase test is that it is ultra sensitive. It can detect cancer when it is at the cellular stage instead of the tumor stage. It can take 5-10 years for a tumor to develop and be seen on an x-ray or in blood work. This Nagalase test significantly accelerates detection time.
This test can also be used for monitoring the effect of therapy of cancer and certain viral infections, including but not limited to HIV & Autism.
6. THERMOGRAPHY IN COMBINATION WITH ULTRASOUND AND COMPUTERIZED REGULATION ANALYSIS
Microcalcifications in breast tissue indicate an increased risk for the development of certain breast cancers. Studies have shown that abnormal thermal patterns represent a far more reliable risk factor than family history (Gautherie, 1995).
The combination thermography and ultrasound is safe and effective in detecting early breast cancer, years before what a mamograms ability to detect breast cancer and with a higher accuracy rate and lower toxicity. Even better, a new thermographic dynamic whole-body detection tool has been perfected for better results. The Institute’s holistic oncology workshop details this new technique. (5)
7. THE PHILIPINE’S NAVARRO URINE (HCG) TEST
Even though HCG is the pregnancy hormone, it can be used as a cancer marker because both carcinogenesis and pregnancy share the activation of this hormone. The Navarro test does not accurately report normals below 5.0mIU/mL. Most cancer patients have HCG levels between 1 and 5. The Navarro’s cut-off point is less than 1.0 and the sensitivity of the immunoradiometric assay (IRMA) is 0.03 mIU/mL. This is one of the cheapest exams in the market (under 60 dollars) and can be used as a cancer marker, even it’s not full proof. To order this test, see this Website.
The Navarro Medical Clinic has been performing the HCG test for cancer for many years and continues to offer this service under the direction of Dr. Efren Navarro. Dr. Efren Navarro, the son of the late Dr. Manuel D Navarro is a graduate of Doctor of Medicine from the University of Santo Thomas, School of Medicine and Surgery, Manila Philippines. He finished his residency in Pathology at Mercy Hospital Medical Center in Chicago. In 1994 he became a Hematopathology Fellow at the University of Illinois, Chicago. In 1996, he returned to the Philippines to continue the work of his famous oncologist father, Manuel Navarro, M.D.
Currently, many cancer patients take advantage of the diagnostic accuracy of the HCG test as an indicator of the effectiveness of their specific mode of therapy. Thousands of cancer survivors have used this test over the years to keep track of their treatment(s) success and check on the status of their remission. Patients follow a simple direction for preparing a dry extract from the urine sample. The powdery extract is mailed to the Navarro Medical Clinic where the HCG testing is performed.
8. FRANCE’S ONCOTEST
Relatively low-tech and inexpensive to perform, the French Oncotest from Dr Beljanski is a relatively low-tech and inexpensive to perform, the Oncotest methodology was first patented by Dr.Mirko Beljanski and then included in his 1983 work «Regulation of DNA Replication and Transcription» published by Karger.
So, when cancerous DNA was exposed to carcinogenic substances, it replicated rapidly, while non-cancerous DNA replicated only slightly. This could be shown experimentally by adding substances to cancerous DNA or normal DNA and measuring either the increase in growth of the DNA or light absorption of the materials, as the more unstable the DNA, the more light that it would absorb (hyperchromicity (see illustration on the right)). Once carcinogens had destabilized normal DNA to the point that it became permanently destabilized (had become cancerous DNA), further exposure to carcinogens would increase the destabilization, making the cancerous DNA unstable. In other words, cancers cells could become more aggressive and bizarre as they were exposed to more carcinogens.”
These observations resulted in Beljanski developing a test to screen substances for carcinogenicity, which he patented in the 70s as the “Oncotest.” Carcinogens resulted in the rapid replication of cancerous DNA, but affected normal DNA only slightly. Most importantly, the Oncotest revealed that a compound could show carcinogenic properties (by affecting DNA structure) without necessarily being a mutagen, which acts by altering DNA and protein sequences. The Oncotest was ultimately used to test hundreds of compounds for their effect on DNA stability and their potential to act as carcinogens. Relatively low-tech and inexpensive to perform, the Oncotest methodology was first patented by Dr.MirkoBeljanski and then included in his 1983 work «Regulation of DNA Replication and Transcription» published by Karger. (Source)
9. ANIMAL CANCER DETECTION SNIFFING
Of all animals, so far, the evidence shows that dogs are the best to detect early stage cancer in humans. Canine cancer detection is an approach to cancer screening that relies upon the olfactory ability of dogs to detect, in urine or in breath, very low concentrations of the alkanes and aromatic compounds generated by tumors. At the ACR Institute, we are working in getting at least one dog or cat that can be trained in this skill. For the details, see Source.
Among others, see the Institute’s workshops for many more early detection diagnostic tests.
COMPLEMENTARY TESTS TO CHECK RELATED CANCER ISSUES
1. CRP TEST
C- Reactive Protein, (CRP) blood marker measuring inflammation, has long been thought of as a marker for cardiovascular disease, but updated research has shown us that it is a critical marker for cancer as well. Elevated CRP level is associated with a reduced survival rate with cancers because inflammation is one of the drivers of the malignancy process. CRP is now recognized as an inflammatory marker but it is also a cause of inflammation. CRP is a protein that is synthesized in the liver and is produced by the Immune Cells and fat cells. It is a very sensitive marker that indicates the levels of inflammation in the body. Inflammation is a precursor to the development of cancer. Think of inflammation as a slow burning fire that is fueled by too much omega 6s, bad diet, sugar intake, stress, toxins, and lack of sleep. As the inflammation rises it can initiate the initiation and progression of cancer.
2. 25-HYDROXY VITAMIN D TEST (25-hydroxycholecalciferol test)
The 25-hydroxy vitamin D test is the most accurate way to measure how much vitamin D is in your body. In the kidney, 25-hydroxy vitamin D changes into an active form of the vitamin. The active form of vitamin D helps control calcium and phosphate levels in the body. The normal range of vitamin D is measured as nanograms per milliliter (ng/mL). Many experts recommend a level between 20 and 40 ng/mL. Others recommend a level between 30 and 50 ng/mL. Cancer patients have a very low level of vitamin D. Unless there is a liver or kidney disease or the patient is taking certain drugs like phenytoin, phenobarbital, and rifampin, vitamin D deficiency can be corrected with sunlight, supplement, diet and other techniques. For more, see this Source.
3. MELATONIN PROFILE TEST
Sleeping correctly is essential in holistic cancer therapy. Furthermore, melatonin is one of the strongest antioxidants the body has. In Italy, a hospital abundantly uses melatonin to better control and reverse cancer. In this perspective, the Comprehensive Melatonin Profile is a convenient, non-invasive salivary hormone test that analyzes the circadian secretion patterns of melatonin. Using a complete light-dark cycle, this hormone test reveals abnormal levels of melatonin that relates to various physical and psychological symptoms as well as premature acceleration of the body´s aging process. Genova Diagnostics´ Comprehensive Melatonin Profile offers many distinct clinical advantages. This hormone test analyzes three saliva specimens taken at morning, noon, and midnight. This type of hormone testing allows for evaluation of melatonin activity of a complete light-dark cycle. It also measures salivary levels which correlate well with serum testing. This hormone test offers a safe, economical, and non-invasive way of assessing pineal function and melatonin secretion patterns
Melatonin is synthesized within the pineal gland from tryptophan during the dark phase of the day. With its unique ability to pass through all blood barriers in the body, melatonin acts as the central hub of physiological function. Once hormonal imbalances have been identified, results can be used to design and implement successful therapeutic programs, including timed application of bright light, removal of interfering factors, and melatonin administration. Melatonin imbalances have been associated with a wide array of health problems, including, but not limited to cancer, sleep disorders, depression, seasonal Affective Disorder (SAD), chronic progressive multiple sclerosis and menstrual irregularities. Melatonin also orchestrates the complex interactions between the mind, body, and environment while it influences most of the autonomic, hormonal, and behavioral functions of the human organism, including by advancing sleep time and duration, by modulate annual and circadian biorhythms (thereby reducing symptoms of jet-lag), by regulate the body temperature, cardiovascular function, immune function and female reproductive hormones.
Melatonin´s synthesis and secretion can be strongly influenced by day length, artificial illumination, electromagnetic energy, exercise, seasonal changes, impairment in methionine metabolism, and aging. Since synthesis and secretion are easily disrupted, accurate assessment of levels and circadian rhythm can be significant.
4. ORAL HYGIENE TESTS
As different cancer experts have shown (6), oral hygiene is needed for one’s immune system to function correctly. Thus mercury amalgams, root canals and other areas of infection need to be tested and corrected.
1. False positives for cancer occur when a screening test finds something that looks like cancer, but that turns out to be non malignant. For example, research has shown that the more mammograms a woman has, the more likely she is to have a false positive result that will require follow up tests. Studies have shown the chances of having a false positive result after 10 yearly mammograms are about 50 to 60 percent (Source). As for prostate cancer, the U.S. Preventive Services Task Force (USPSTF) recommends AGAINST prostate-specific antigen (PSA)-based screenings for prostate cancer. The benefits of PSA-based screening for prostate cancer do not outweigh the negatives. The high likelihood of false-positive results from a PSA test, coupled with its inability to distinguish indolent from aggressive tumors, means that a substantial number of men undergo biopsy and are over-diagnosed with and over-treated for prostate cancer.
2. One of the problems with conventional oncology is that the doctors have used a “one-size-fits-all” approach and therefore the drugs too often fail with life altering consequences. With chemo-sensitivity and genomic testing, some semblance of “precision” and individualized medicine is achieved. The personalized approach is to identify the circulating Tumor Cells, (CTCs) and Cancer Stem Cells (CSCs) to see what natural and chemical substances they are most sensitive to. The procedure consists in remove some of the patient’s blood which can then be harvested so that cancer cells and the cancer stem can be grown in petri dishes, where various pharmaceutical and natural substances are introduced. After 48 hours, each substance is measured to see how effective it is in terms of cancer cell and cancer stem cell apoptosis or necrosis. In this realm, the most popular test is the GreekTest which checks 49 chemo drugs and 50 natural biologic substances such as enzymes, Poly MVA, Vitamin D3, fermented soy extract, mistletoe, SOD, burdock complex, B 17. The patient also have the option of sending 2 specific natural substances that are not on the Greek test list. Based on the results of the test, the practitioner can learn the following: (a) which specific genes are involved in the growth of the cancer, (b) the effectiveness of drugs and natural substances. Thanks to this data, a precise and individualized protocol can be ascertained. Sloane Kettering and the University of Texas MD Anderson Cancer Center in Houston are beginning to use the test after have received a $15 million dollar grant from the Stand up to Cancer Telethon. For more details, see this Source.
3. The uniqueness of the Cancer Profile is that it combines a number of tests which, by themselves, might not be indicative enough, but together provide an impressive level of accuracy and precision.Looking at three cancer markers together (HCG, PHI, CEA), 221 positives in 240 breast cancer patients (92 percent) were detected. Of lung-cancer patients, 127 of 129 (97 percent) were correctly diagnosed. And with colon-cancer patients, 55 positives out of 59 patients (93 percent) were correctly identified. In this perspective, a study reported in 1987 a tumor marker CEA showed to be sensitive in cases of metastasized bone cancer, while PHI was elevated in cancers of other organs. However, when CEA and PHI were combined, overall sensitivity was increased considerably [Paulick, R., et al., Cancer Detect Prev, 1987, 10 (3-4): 197-203].
4. This test measures the activity of alpha-N-acetylgalactosaminidase (nagalase) in blood. Nagalase is an extracellular matrix-degrading enzyme that is (increased) secreted by cancerous cells in the process of tumor invasion. It also is an intrinsic component of envelope protein of various virions, such as HIV and the influenza virus. It is secreted from virus-infected cells. (…) Increased activity of nagalase has been detected in the blood of patients with a wide variety of cancers, like cancer of the prostate, breast, colon, lung, oesophagus, stomach, liver, pancreas, kidney, bladder, testis, uterus and ovary, mesothelioma, melanoma, fibrosarcoma, glioblastoma, neuroblastoma and various leukeamias. For various types of tumors various levels of nagalase activity were found.7 It seems likely that secretory capacity of individual tumor tissue varies among tumor types depending upon tumor size, staging, and the degree of malignancy or invasiveness.7 Increased nagalase activity has not been detected in the blood of healthy humans. (….) It has been established that the nagalase activity is directly proportional to viable tumor burden. Studies correlating nagalase levels with tumor burden suggest that the measurement of this enzyme can diagnose the presence of cancerous lesions below levels detectable by other diagnostic means. In research a day after surgical removal of primary tumors from cancer patients nagalase activity suddenly decreased to near the tumor-free control level, suggesting that the half-life value of nagalase is less than 24 hours.1,6 The short half-life of nagalase is valuable for prognosis of the disease during various therapies. (Source)
5. The first recorded use of thermobiological diagnoses can be found in the writings of Hippocrates around 480 BC. Mud was preadover the patient and areas that would dry first were thought to indicate underlying organ pathology. Over time continued research and clinical observations proved that certain temperatures and temperature behaviors were indicative of normal and abnormal physiological processes. In the U.S., the first diagnostic use of infrared imaging was in 1956 when Lawson discovered that the skin temperature over a cancer was higher than that of normal tissue. He showed the venous blood draining from the tumor site is often warmer than its arterial supply. In 1982 the FDA published its approval and classification of thermography as an adjunctive diagnostic screening procedure. Since then it has been cleared for several indications such as neoplastic disorders and inflammatory conditions, as well as thyroid dysfunction, neuromuscular disease and breast disorders. Yet, the gold standard detection tools are still mamograms and the like.
6. Biological dentistry took root in Germany. See Dr Rau of Paracelsus clinic and Dr Klinghard websites for additional details.
Nothing in this educational blog should be construed as medical advise.
2016 Copyright: ACRI (Advanced Cancer Research Institute) and agents. All rights reserved.